BRAND: Emtricitabine/Tenofovir disoproxil Rowex
ACTIVE INGREDIENT: Emtricitabine/Tenofovir disoproxil
STRENGTH & PACK SIZE & GMS CODES:
200 mg/245 mg Film-coated Tablets x 30
INDICATION:
Treatment of HIV-1 infection:
Emtricitabine/Tenofovir disoproxil Rowex is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.
Emtricitabine/Tenofovir disoproxil Rowex is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to <18 years.
Pre-exposure prophylaxis (PrEP):
Emtricitabine/Tenofovir disoproxil Rowex is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
Download Emtricitabine/Tenofovir disoproxil Rowex 200mg SPC here
Download Emtricitabine/Tenofovir disoproxil Rowex 200mg Leaflet here